Policy | December 04, 2025
Promotion of indigenous pharmaceutical manufacturing
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative
Additional capacity broadens Grace’s fine chemical capabilities for API production
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
Subscribe To Our Newsletter & Stay Updated
